Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Capecitabine + Gemcitabine + Tertomotide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Capecitabine||Xeloda||R340||Chemotherapy - Antimetabolite 11||Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary).|
|Gemcitabine||Gemzar||Difluorodeoxycytidine Hydrochlorothiazide|LY-188011||Chemotherapy - Antimetabolite 11||Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).|
|Tertomotide||GV1001||Tertomotide (GV1001) is a 16-amino acid peptide of human telomerase reverse transcriptase (hTERT) that may induce immune response against hTERT-expressing ccancer cells (PMID: 23295993), and can also act as a ligand for gonadotropin-releasing hormone receptor (GnRHR) and thus inhibit prostate cancer cell growth (PMID: 30400054).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic cancer||no benefit||Capecitabine + Gemcitabine + Tertomotide||Phase III||Actionable||In a Phase III trial (TeloVac), addition of Tertomotide (GV1001) sequentially or concurrently to chemotherapy consisting of Xeloda (capecitabine) and Gemzar (gemcitabine) did not improve median overall survival compared to chemotherapy alone (6.9, 8.4, and 7.9 months, respectively) in patients with locally advanced or metastatic pancreatic cancer (PMID: 24954781).||24954781|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|